A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non‐small cell lung cancer patients

Paclitaxel/platinum chemotherapy, the backbone of standard first‐line treatment of advanced non‐small cell lung cancer (NSCLC), exhibits high interpatient variability in treatment response and high toxicity burden. Baseline blood biomarker concentrations and tumor size (sum of diameters) at week 8 r...

Descripción completa

Detalles Bibliográficos
Autores principales: Ojara, Francis Williams, Henrich, Andrea, Frances, Nicolas, Nassar, Yomna M., Huisinga, Wilhelm, Hartung, Niklas, Geiger, Kimberly, Holdenrieder, Stefan, Joerger, Markus, Kloft, Charlotte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681433/
https://www.ncbi.nlm.nih.gov/pubmed/36782356
http://dx.doi.org/10.1002/psp4.12937

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681433/
https://www.ncbi.nlm.nih.gov/pubmed/36782356
http://dx.doi.org/10.1002/psp4.12937

Ejemplares similares